May 22nd 2025
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Watch the series now!
Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers
Breast Cancer Death Rates Drop, but Racial Disparities Linger
Why You Should Attend Patient-Centered Oncology Care in Baltimore